Formosa Laboratories, Inc. Formosa Laboratories, Inc.

Formosa Laboratories, Inc.

4746

Rank in Stocks #18527
Formosa Laboratories, Inc., together with its subsidiaries, engages in the... Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
Share Price
$1.42
Last synced: 2026-11-13
Market Cap
$129.95M
Change (1 day)
1.87%
Change (1 year)
-33.23%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Formosa Laboratories, Inc. (4746)

Category

Healthcare
Operating Margin for Formosa Laboratories, Inc. (4746)
Operating Margin as of November 2026 TTM: 9.80%
According to Formosa Laboratories, Inc.'s latest financial reports, its current operating margin (TTM) is 9.80%. At the end of 2025 the company had an operating margin of 16.56%.
Operating Margin history for Formosa Laboratories, Inc. from 2010 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 9.80% -40.82%
2025 16.56% 4.48%
2024 15.85% 2.39%
2023 15.48% 53.12%
2022 10.11% -71.16%
2021 35.06% 156.47%
2020 13.67% -17,187.50%
2019 -0.08% -103.76%
2018 2.13% -85.70%
2017 14.89% -28.41%
2016 20.80% 65.87%
2015 12.54% 14.31%
2014 10.97% -462.05%
2013 -3.03% -307.53%
2012 1.46% -84.28%
2011 9.29% -27.54%
2010 12.82% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
59.80% -93.90%
US
31.60% -96.78%
SE
30.13% -96.93%
FR
29.76% -96.96%
HK
31.11% -96.83%
IT
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Formosa Laboratories, Inc.'s operating margin

What is Formosa Laboratories, Inc.'s operating margin?

Formosa Laboratories, Inc.'s operating margin is 9.80%, as of Nov 2026.

What was Formosa Laboratories, Inc.'s operating margin in 2025?

In 2025, Formosa Laboratories, Inc.'s operating margin was 16.56%, compared with 15.85% in 2024.

How has Formosa Laboratories, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Formosa Laboratories, Inc.'s operating margin was highest in 2021 (35.06%) and lowest in 2022 (10.11%).

How does Formosa Laboratories, Inc.'s operating margin compare with similar companies?

Formosa Laboratories, Inc.'s operating margin (9.80%) is lower than that of all 5 similar companies listed above. The highest among them is Royalty Pharma plc, with 59.80%.